Quick navigation menu :

  1. Go to the content
  2. Go to main section's menu
  3. Go to Search tool
  4. Go to Help menu
  5. Go to modules
  6. Go to the list of keyboard shortcuts

This site uses cookies to store information on your computer. Some cookies on this site are essential and the site won’t work as expected without them. To learn more about cookies and their benefits, please view our cookies policy. You could also decide what kind of cookie the website could use or not use on our cookies settings page.
By closing this message or navigating within the website, you consent to our use of cookies on this device in accordance with our cookie policy unless you have disabled them.

Help menu :

  1. Sanofi Worldwide |
     
  2. Our UK Websites |
     
  3. Global Business Websites |
     
  4. Contact us |
  5. Site map |
  6. Help
  1. RSS
  2. Font size

    Reduce font size Increase font size  
 
 

Content :

Public Disclosure of Payments

June 28, 2016

Payments made to Healthcare Professionals, Healthcare Organisations and Patient Associations

 

As a global healthcare leader, at Sanofi we recognise our responsibility for transparency in our working relationships with healthcare professionals, patient associations and healthcare organisations.

Why is transparency important?

Collaboration between industry, healthcare professionals and healthcare organisations is a vital need in enabling the development and effective use of new medicines and shaping the future of research. Bringing greater transparency to these already well-regulated and legitimate relationships aims to build greater understanding of the collaboration between industry, healthcare professionals and healthcare organisations. We are committed to greater transparency in our industry and will continue to strive for the highest possible standards

Why are we working with healthcare professionals, healthcare organisations and patient associations?

The healthcare professionals, healthcare organisations and patient associations with whom we work provide us with valuable, independent and expert knowledge derived from their clinical and disease management experience. We are dedicated to delivering a high quality service to patients who are at the centre of our business decisions. Collaborating with experts contributes significantly to our efforts to improve the quality of patient care, with benefits for individuals and society at large.

What is Sanofi’s commitment in regards to transparency?

We believe that transparency reflects on credibility and engenders confidence in our company, and we are committed to complying with all applicable rules and regulations governing transparency.

As of June 2016, and as a member company of EFPIA, Sanofi is disclosing details of its collaborations with healthcare professionals and healthcare organisations across Europe. The disclosures include transfers of value made for activities such as research and educational grants to healthcare organisations as well as transfers of value to individual HCPs such as sponsorship to attend educational meetings, speaker fees, consultancy activities and advisory boards.

As a UK affiliate, under both our obligations with the EFPIA Disclosure Code and ABPI Code of Practice, we are listing all the transfers of value (payments which can be direct, indirect or in kind) made to healthcare organisations, patient associations, healthcare professionals and research and development in 2015.

Therefore, in-line with the rest of the pharmaceutical industry, all transfers of value to healthcare organisations from 2015 will be held on the ABPI website and no longer available on sanofi.co.uk.

From 1 July 2016, all transfers of value made by Sanofi to named individual healthcare professionals will be available on the ABPI website except for individuals who have not consented to place their data in the public domain. Transfers of value made to individual healthcare professionals who have not consented to this will be disclosed in an aggregated pool.

Our annual breakdown of transfers of value to patient associations will continue to be posted on this website. The data for 2015 is now available - see link below.

Links to further public disclosure information

 

Date: June 2016 – Job Code: SAGB.SA.16.05.0470

Module :

Corporate Information

Corporate Information

 

Sanofi in the UK

Find out more about Sanofi UK's business units and locations, our investment in research and development, and our product pipeline